Keros Therapeutics to Participate in Two Upcoming Healthcare Conferences
LEXINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in two upcoming healthcare conferences.
Event: Morgan Stanley 19th Annual Global Healthcare Conference
Date/Time: Friday, September 10 at 11:00 AM ET
Format: Fireside Chat
Event: H.C. Wainwright 23rd Annual Global Investment Conference
Date/Time: Available on Monday, September 13 starting at 7:00 AM ET
Format: Corporate Presentation
The Morgan Stanley fireside chat presentation will be webcast live at https://morganstanley.webcasts.com/starthere.jsp?ei=1488923&tp_key=f6a26a9322 and the H.C. Wainwright presentation will be available at https://journey.ct.events/view/2af63db8-a98e-40f7-bb4e-4fc6d4b18ba0. Both will be archived in the Investors section of the Keros website at https://ir.kerostx.com/. A replay will be available for 90 days following the conclusion of the event.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need. Keros is a leader in understanding the role of the transforming growth factor-Beta, or TGF-ß, family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros’ lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros’ lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from iron imbalance, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros’ third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.